Maze Therapeutics, Inc. (MAZE)
Nasdaq: MAZE · Biological Products, (No Diagnostic Substances) · South San Francisco, CA · filing with the SEC since 2024
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 |
|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 |
| Report filed | Mar 25, 2026 | Mar 31, 2025 |
| Revenue | · | 167,500 |
| Research and development | 108,448 | 83,496 |
| General and administrative | 34,451 | 26,418 |
| Total operating expenses | 142,899 | 109,914 |
| Operating income | -142,899 | 57,586 |
| Income before income taxes | -131,120 | 53,403 |
| Income tax expense | 0 | 1,172 |
| Net income including non-controlling interests | -131,120 | 52,231 |
| Net income | -131,120 | 52,231 |
| Net income to common shareholders | -131,120 | 3,405 |
| Earnings per share, basic | -3.05 | 1.42 |
| Earnings per share, diluted | -3.05 | 1.25 |
| Weighted average shares, basic | 42,976,024 | 2,396,094 |
| Weighted average shares, diluted | 42,976,024 | 2,730,299 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding